BY FORMAT The GLP-1 agonists market is segmented by format into single-dose, multi-dose, and tablet forms
Those included: Nausea (about 29 to 42 percent of participants, depending on the dose) Diarrhea (25 to 34 percent) Constipation (24 to 26 percent) Vomiting (11 to 25 percent) Upper respiratory tract infection (12 to 14 percent) Interestingly, more people taking a placebo dropped out of the trial because of side effects than participants taking the lowest dose of retatrutide (4.9 percent compared with 4.1 percent)
Women may experience changes in cycle timing, flow intensity, missed periods, or breakthrough bleeding as the body adjusts to new metabolic parameters
Placebo: -2.1%
[37] [38] See also [edit source] Dipeptidyl peptidase-4 Gastric inhibitory polypeptide GLP-1 receptor agonistsalbiglutide, dulaglutide, exenatide, liraglutide, lixisenatide, tirzepatide, and semaglutide, the last of which is marketed under the brands Ozempic, Rybelsus, and Wegovy
Common Adverse Events The most common adverse events in Phase 2 trials were gastrointestinal in nature, reflecting the class effects of GLP-1 receptor activation on gastric motility and central appetite pathways
